BIOMAT Database Logo BIOMAT Database Logo

Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. 1998

D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.

The current human whole-cell vaccine is ineffective against pneumonic plague caused by typical F1 capsule positive (F1+) strains of Yersinia pestis. The authors found this vaccine to also be ineffective against F1-negative (F1-) Y. pestis strains, which have been isolated from a human case and from rodents. For these reasons, the authors developed a recombinant vaccine composed of a fusion protein of F1 with a second protective immunogen, V antigen. This vaccine protected experimental mice against pneumonic as well as bubonic plague produced by either an F1+ or F1- strain of Y. pestis, gave better protection than F1 or V alone against the F1+ strain, and may provide the basis for an improved human plague vaccine.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D010930 Plague An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form. Bubonic Plague,Meningeal Plague,Pneumonic Plague,Pulmonic Plague,Black Death,Black Plague,Septicemic Plague,Yersinia pestis Infection
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species

Related Publications

D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
January 2005, Biotechnology progress,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
June 2011, Vaccine,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
October 2008, Infection and immunity,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
November 1996, Infection and immunity,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine.
May 2006, Vaccine,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Vaccination against bubonic and pneumonic plague.
July 2001, Vaccine,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
January 2007, Vaccine,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
January 2015, PLoS neglected tropical diseases,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis.
April 1997, The American journal of tropical medicine and hygiene,
D G Heath, and G W Anderson, and J M Mauro, and S L Welkos, and G P Andrews, and J Adamovicz, and A M Friedlander
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
January 2007, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!